Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1

Meina Liang, Cornell Mallari, Mary P. Rosser, Howard P. Ng, Karen May, Sean Monahan, John G. Bauman, Imadul Islam, Ameen Ghannam, Brad O. Buckman, Ken Shaw, Guo-Ping Wei, Wei Xu, Zuchun Zhao, Elena Ho, Jun Shen, Huynh Oanh, Babu Subramanyam, Ron Vergona, Dennis D. Taub, Laura Dunning, Susan Harvey, R. Michael Snider, Joseph Hesselgesser, Michael M. Morrissey, H. Daniel Perez, Richard HorukJournal of Biological Chemistry 2000 · DOI

Abstract

The CC chemokine receptor-1 (CCR1) is a prime therapeutic target for treating autoimmune diseases. Through high capacity screening followed by chemical optimization, we identified a novel non-peptide CCR1 antagonist, R-N-[5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl ]-2-oxoethoxy]phenyl]urea hydrochloric acid salt (BX 471). Competition binding studies revealed that BX 471 was able to displace the CCR1 ligands macrophage inflammatory protein-1alpha (MIP-1alpha), RANTES, and monocyte chemotactic protein-3 (MCP-3) with high affinity (K(i) ranged from 1 nm to 5.5 nm). BX 471 was a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca(2+) mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration. BX 471 demonstrated a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. Pharmacokinetic studies demonstrated that BX 471 was orally active with a bioavailability of 60% in dogs. Furthermore, BX 471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. This study is the first to demonstrate that a non-peptide chemokine receptor antagonist is efficacious in an animal model of an autoimmune disease. In summary, we have identified a potent, selective, and orally available CCR1 antagonist that may be useful in the treatment of chronic inflammatory diseases.
BibTeX
@article{liang2000identification,
  author = {Meina Liang and Cornell Mallari and Mary P. Rosser and Howard P. Ng and Karen May and Sean Monahan and John G. Bauman and Imadul Islam and Ameen Ghannam and Brad O. Buckman and Ken Shaw and Guo-Ping Wei and Wei Xu and Zuchun Zhao and Elena Ho and Jun Shen and Huynh Oanh and Babu Subramanyam and Ron Vergona and Dennis D. Taub and Laura Dunning and Susan Harvey and R. Michael Snider and Joseph Hesselgesser and Michael M. Morrissey and H. Daniel Perez and Richard Horuk},
  title = {{Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1}},
  journal = {Journal of Biological Chemistry},
  year = {2000},
  doi = {10.1074/jbc.m001222200},
}

Loading related content...

Figure